Compare Tango Therapeutics Inc. (TNGX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Verisign, Inc. — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Verisign, Inc. trades at $302.35 (market cap $27.28B). The key difference: Verisign, Inc. is far larger — about 7.3× Tango Therapeutics Inc.'s market cap, and Verisign, Inc. pays a 1.07% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Verisign, Inc. for 124 Days on average.
| TNGX | VRSN | |
|---|---|---|
Market Cap | $3.75B | $27.28B |
Volume | 9,619,106 | 695,583 |
Sector | Health | Technology |
52-Week High | $32.90 | $310.00 |
52-Week Low | $7.50 | $211.49 |
Typical Hold Time | 0 Days | 124 Days |
Enterprise Value | $2.77B | $28.59B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VeriSign (VRSN) trades at $301.41, down 0.43% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $348. The stock shows strong profitability with a net income margin near 50% and consistent revenue growth, though recent quarterly EPS results have been mixed. Key developments include an upcoming Q3 2026 earnings report and ongoing institutional accumulation, balanced by an antitrust lawsuit and insider selling activity.
The outlook for VRSN remains positive given its dominant market position and high margins, with potential upside to analyst targets. Risks include legal challenges, competitive pressures, and valuation multiples above industry averages. Earnings performance and resolution of regulatory issues will be critical near-term catalysts for the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
